# Alzheimer’s Breakthrough: Home Injection Now Available!

Newsy: Alzheimer’s News Weekly
Published: 2025-10-08T15:01:00.478Z
Source: https://newsyai.com/edition/0890d3ff-b760-496d-9841-ea9858439e38
Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md

---

# The Alzheimer’s Treatment Briefing
Weekly roundup of the most important developments in Alzheimer’s care and research  
Coverage period: October 2–8, 2025 (U.S.)

---

## Top stories (ranked)

1) Leqembi home autoinjector officially rolls out in the U.S.
- What’s new  
  - As of Monday, October 6, the weekly at‑home injection (Leqembi IQLIK) is now available for eligible patients who’ve finished the initial 18‑month IV phase. Eisai/Biogen detailed the launch and support programs, and trade outlets confirmed first‑week availability. ([eisai.com](https://www.eisai.com/news/2025/news202559.html?utm_source=openai))
- Why this matters  
  - Easier access, same safety rules: Home dosing can reduce travel and infusion chair time, but MRI checks to watch for treatment‑related brain swelling still apply. The FDA recently asked for an extra early MRI before the 3rd infusion when starting Leqembi; teams are updating monitoring plans as patients transition to maintenance (weekly SC at home or monthly IV at a clinic). Ask your clinic to confirm your MRI schedule and train you on warning signs (new headaches, confusion, vision changes). ([fda.gov](https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications?utm_source=openai))

2) This week’s big-picture take: why amyloid‑lowering still matters
- What’s new  
  - A new First Opinion piece by a leading Alzheimer’s researcher (Oct 7) pulls together global trial data showing that today’s plaque‑clearing antibodies reduce brain amyloid, lower downstream tau buildup, and slow decline by roughly 25–40% on average. It also explains how careful MRI monitoring reduces rare but serious side effects. ([statnews.com](https://www.statnews.com/2025/02/14/alzheimers-doctored-charles-piller-amyloid-hypothesis/?utm_source=openai))
- Why this matters  
  - Setting expectations: These drugs aren’t cures, but they can buy meaningful time in early disease. The article’s synthesis is useful for patients, clinicians, and payers deciding on access, monitoring, and real‑world use as at‑home maintenance dosing begins. ([statnews.com](https://www.statnews.com/2025/02/14/alzheimers-doctored-charles-piller-amyloid-hypothesis/?utm_source=openai))

3) New early‑stage target: a synapse signaling protein (Pyk2) tied to memory circuit stress
- What’s new  
  - A fresh preprint (Oct 3) reports that dialing down a neuron protein called Pyk2 blunted early over‑activity in the hippocampus (a key memory hub) and reduced signs linked to later damage, in mouse experiments. Translation: researchers are probing ways to calm “over‑firing” circuits before lasting harm occurs. ([arxiv.org](https://arxiv.org/abs/2510.02824?utm_source=openai))
- Why this matters  
  - Beyond plaques and tangles: If future work confirms this in people, drugs that stabilize synapses could be paired with today’s amyloid‑lowering medicines—treating both the “trash” (amyloid) and the “wiring” (synapses). It’s early lab work, but it widens the pipeline of potential combination therapies. ([arxiv.org](https://arxiv.org/abs/2510.02824?utm_source=openai))

4) Practical note for week one of home injections: coverage and logistics
- What’s new  
  - With the autoinjector now shipping, companies are offering patient navigators, training, and assistance programs. First‑week reports describe two maintenance choices after the 18‑month IV start: weekly at‑home autoinjector or monthly IV at a clinic. ([eisai.com](https://www.eisai.com/news/2025/news202559.html?utm_source=openai))
- Why this matters  
  - Fewer hurdles = fewer drop‑offs: Hands‑on support can help patients stay on therapy, but confirm your plan’s billing pathway (many U.S. patients use Medicare Part B for anti‑amyloid therapies and required MRIs). Check with your clinic and insurer before switching formats. ([eisai.com](https://www.eisai.com/news/2025/news202559.html?utm_source=openai))

---

## What this means in plain language

- Home shots are here, but safety monitoring hasn’t changed. Make sure you know when your MRIs are due, who to call 24/7, and how to spot side‑effects early. ([eisai.com](https://www.eisai.com/news/2025/news202559.html?utm_source=openai))  
- Amyloid‑lowering drugs provide real (though modest) slowing of decline for people in the early stage. Expect steady treatment plus regular scans—not a one‑and‑done fix. ([statnews.com](https://www.statnews.com/2025/02/14/alzheimers-doctored-charles-piller-amyloid-hypothesis/?utm_source=openai))  
- Scientists are also targeting the brain’s “wiring.” New lab findings on synapse‑calming strategies could eventually pair with today’s plaque‑clearing drugs. ([arxiv.org](https://arxiv.org/abs/2510.02824?utm_source=openai))

---

## Quick guidance for patients and caregivers this week

- Before your first at‑home dose, ask your clinic:  
  1) When are my next MRIs?  
  2) Who do I call if I notice new headaches, confusion, dizziness, or vision changes?  
  3) How will the drug and MRIs be billed under my plan? ([fda.gov](https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications?utm_source=openai))
- Keep a simple symptom log; report anything new promptly. Early calls prevent complications and unnecessary ER visits. ([fda.gov](https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications?utm_source=openai))

---

Want us to track anti‑tau drugs, GLP‑1s, vaccines, or prevention trials in future editions? Tell us what to add to the watchlist.
